Subcutaneous abaloparatide viable option for postmenopausal women with osteoporosis – Healio

Subcutaneous abaloparatide viable option for postmenopausal women with osteoporosisHealioPostmenopausal women with osteoporosis treated with subcutaneous abaloparatide for 18 months followed by alendronate for 6 months had improved bone mineral density and a reduced risk for fracture, according to findings from the ACTIVExtend study.

Source:: Osteoporosis Feed

      

Last modified: February 3, 2017